Chlamydia RNA Test

Chlamydia is the most common bacterial sexually transmitted infection in the world, and the reason it spreads so effectively is that most people who have it feel completely fine. About 70% of infected women and roughly 50% of infected men have no symptoms at all. That silence is what makes it dangerous. Left undetected, this single bacterium can cause irreversible damage to the reproductive tract, including scarring that blocks the fallopian tubes and leads to infertility or life-threatening ectopic pregnancies.

This test uses a technology called TMA (transcription-mediated amplification) to detect RNA from the bacterium Chlamydia trachomatis in a urine sample or urogenital swab. Because it targets RNA, a molecule present in large quantities in actively multiplying bacteria, the test is extremely sensitive. It can pick up an infection from a simple urine sample or a self-collected swab, making it one of the easiest and most reliable screening tools available.

How This Test Works

The TMA assay targets a specific piece of genetic material, the 23S ribosomal RNA, that belongs to Chlamydia trachomatis and nothing else in your body. The test amplifies tiny amounts of this RNA so that even a very early or low-level infection can be caught. The result is straightforward: detected (positive) or not detected (negative). There is no scale, no range, and no gray zone in the way that cholesterol or blood sugar tests have.

Across multiple validation studies, TMA-based testing achieves 88 to 100% sensitivity and 99.5 to 100% specificity for urogenital specimens. In practical terms, if you have an active chlamydia infection and provide the right specimen, this test will almost certainly find it. And if you do not have the infection, it will almost never say you do.

Pelvic Inflammatory Disease and Fertility

The most serious consequence of untreated chlamydia in women is pelvic inflammatory disease (PID), an infection that spreads from the cervix into the uterus and fallopian tubes. About 10% of women with untreated chlamydia develop PID within a year. PID causes inflammation and scarring that can permanently alter the architecture of the reproductive tract.

The damage compounds with each episode. After one bout of PID, about 8% of women develop tubal factor infertility, meaning the fallopian tubes are too scarred or blocked for an egg to pass through. After two episodes, that number rises to roughly 23%. After three, it reaches about 43%. Women with a history of PID also report chronic pelvic pain at roughly three times the rate of women without it.

A large Dutch prospective study following 5,704 women for up to 14 years found that symptomatic chlamydia infection raised the risk of PID by about 2.3-fold and the risk of tubal factor infertility by about 2.75-fold. A separate Danish national study of over 516,000 women confirmed that women who tested positive for chlamydia had roughly 50% higher rates of PID and 31% higher rates of ectopic pregnancy compared to women who tested negative, and these elevated risks persisted across 17 years of follow-up.

Ectopic Pregnancy

When the fallopian tubes are damaged by infection, a fertilized egg can implant inside the tube instead of reaching the uterus. This is called an ectopic pregnancy, and it is a medical emergency that can cause life-threatening bleeding. Nearly 10% of first pregnancies following PID are ectopic. In the Dutch prospective study, women with a history of chlamydia had an 84% higher risk of ectopic pregnancy compared to uninfected women.

Cervical Cancer Risk

Chlamydia infection also appears to amplify the cancer-causing effects of HPV (human papillomavirus). A meta-analysis of 22 studies including over 4,200 cervical cancer cases found that women with a history of chlamydia had about twice the risk of cervical cancer. When chlamydia and HPV were both present, the risk was roughly four times higher than in women with neither infection. The association held even after controlling for HPV status and age, though it was somewhat weaker after adjustment.

Consequences in Men

While the reproductive consequences are more severe and better documented in women, chlamydia is not harmless in men. It is the leading cause of epididymitis (inflammation of the tube behind the testicle that stores sperm) in sexually active men under 35, and it commonly causes urethritis (inflammation of the urethra). In both sexes, untreated chlamydia also increases susceptibility to HIV transmission.

Who Should Be Screened and When

Because the infection is usually silent, you cannot rely on symptoms to tell you whether you need testing. The U.S. Preventive Services Task Force and the CDC recommend annual screening for all sexually active women under 25. Women 25 and older should be screened if they have risk factors such as a new sexual partner, multiple partners, a partner with a known STI, or inconsistent condom use. Men who have sex with men should be screened at least annually, and every 3 to 6 months if at higher risk.

All pregnant women should be screened at their first prenatal visit, because untreated chlamydia during pregnancy is linked to preterm delivery, premature rupture of membranes, and low birth weight. If risk factors persist, retesting in the third trimester is recommended.

If you are sexually active and have never been tested, you should know your status now rather than waiting for a reason. A randomized trial of over 63,000 young adults found that chlamydia screening reduced hospital-diagnosed PID by 40%. That is the value of catching this infection early: you prevent damage that cannot be undone.

Specimen Type Matters

For women, self-collected vaginal swabs are now considered the preferred specimen type because they capture the highest bacterial load. Urine testing works, but studies show that female urine specimens can miss up to 10% of infections that a vaginal swab would catch. For men, first-void urine (the initial stream when you begin urinating) is the standard specimen. Using mid-stream urine instead can reduce sensitivity.

When Results Can Be Misleading

This test is highly accurate, but a few situations can produce results that do not reflect your true infection status.

• Testing too soon after treatment: The test detects bacterial RNA, which can persist from dead organisms for up to 3 to 4 weeks after successful antibiotic treatment. Testing before this window closes can produce a positive result even though the infection has been cured. This is why routine test-of-cure is not recommended before 4 weeks post-treatment.
• Urinary inhibitors in women: Certain substances naturally present in urine, including hemoglobin, nitrites, and the pregnancy hormone beta-hCG, can interfere with the amplification process. Complete inhibition occurs in roughly 7.5% of female urine specimens, which is another reason vaginal swabs are preferred for women.
• Low-prevalence settings: When chlamydia is rare in the population being tested (such as older adults with long-term monogamous partners), even a test with 99.5% specificity will produce a higher proportion of false-positive results simply because true positives are so uncommon. A borderline positive result in a low-risk person warrants confirmatory testing.
• Environmental contamination: Chlamydia RNA can persist on surfaces for at least 50 days. Contamination during specimen collection, though rare in clinical settings, is theoretically possible.

Retesting After Treatment

A single positive result is diagnostic and should prompt immediate treatment. You do not need a second test to confirm the result before starting antibiotics. However, retesting 3 months after completing treatment is recommended for everyone who tests positive, because reinfection rates are high. Studies consistently show that people treated for chlamydia have a significant risk of testing positive again within the following year, usually because their partner was not treated simultaneously or because of new exposure.

This 3-month retest is not checking whether the antibiotics worked (they almost always do). It is checking whether you have been re-exposed. Think of it as a safety net: if you catch a reinfection quickly, you prevent a second round of potential reproductive damage.